Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis
Cohen S, Goldsmith D, Ning C, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Seidman L, Stone W, Tsuang M, Woods S, Walker E, Miller B. Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis. Psychiatry Research 2024, 341: 116147. PMID: 39197223, DOI: 10.1016/j.psychres.2024.116147.Peer-Reviewed Original ResearchPsychosis-risk symptomsClinical high riskSuicidal ideationCHR-P individualsCHR-PSleep disturbanceTerminal insomniaNorth American Prodrome Longitudinal StudyAssociated with conversion to psychosisSleep problemsConversion to psychosisTreatment of sleep disturbancesAssociated with SIIndices of sleep disturbanceMultiple indicesPsychosisIdeationLongitudinal intervention studyInsomniaLongitudinal studySchizophreniaSymptomsSleepSymptom scoresInvestigate relationshipsPlasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
Byrne J, Healy C, Föcking M, Heurich M, Susai S, Mongan D, Wynne K, Kodosaki E, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, Jeffries C, Perkins D, Cotter D. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain Behavior And Immunity 2024, 119: 188-196. PMID: 38555993, DOI: 10.1016/j.bbi.2024.03.049.Peer-Reviewed Original ResearchNegative symptomsDepressive symptomsScale of Psychosis-risk SymptomsMeasures of negative symptomsNorth American Prodrome Longitudinal Study 2Psychosis-risk symptomsClinical high riskPrognostic factorsLongitudinal Study 2Positive symptomsNAPLS 2Psychotic disordersAntipsychotic usePsychotic experiencesCannabis useSuicidal ideationAntidepressant useStudy 2Regulation groupQuality of life of individualsGroup factorsCurrent treatment optionsDemographic prognostic factorsPsychosisCoagulation proteinsDifferential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms
Healy C, Byrne J, Raj Suasi S, Föcking M, Mongan D, Kodosaki E, Heurich M, Cagney G, Wynne K, Bearden C, Woods S, Cornblatt B, Mathalon D, Stone W, Cannon T, Addington J, Cadenhead K, Perkins D, Jeffries C, Cotter D. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain Behavior And Immunity 2024, 117: 175-180. PMID: 38219978, DOI: 10.1016/j.bbi.2023.12.018.Peer-Reviewed Original ResearchGlobal Assessment of Functioning ScaleNorth American Prodrome Longitudinal StudyClinical high riskPoor functionScale of Psychosis-risk SymptomsPsychosis-risk symptomsAssociated with poorer functioningFirst-episode psychosisTransition to psychosisGreater symptom severityFollow-upIndividuals at-riskClinical symptomsPsychotic disordersHigh riskSymptom severityPsychosocial functioningGlobal functioningPsychosisSubscale scoresFDR correctionAcute phase inflammatory responseLongitudinal studyGlobal assessmentFunctional scales